| Position 2007 (2006) | Pharmacological activity (code) | No of products 2007 (2006) | % PR, R or L |
|---|---|---|---|
| 1 (1) | Immunostimulant (IM-) | 750 (776) | 10 |
| 2 (2) | Angiogenesis inihibitor (ANGG-) | 162 (174) | 8 |
| 3 (3) | Apoptosis agonist (APOP+) | 159 (137) | 4 |
| 4 (4) | DNA antagonist (DNA-) | 107 (96) | 17 |
| 5 (5) | Immunosuppressant (IM-) | 76 (82) | 26 |
| 6 (6) | Topoisomerase 2 inhibitor (TO-2-) | 72 (73) | 21 |
| 7 (8) | Cyclooxgenase 2 inhibitor (OX-C-2-) | 66 (62) | 33 |
| 8 (11) | Sodium channel antagonist (CHA-NA-) | 61 (55) | 21 |
| 9 (14) | Cell wall synthesis antagonist (SY-CW-) | 55 (52) | 31 |
| 10 (12) | Microtubule stimulant (MICTUBE+) | 54 (53) | 13 |
| 11 (17) | Lipocortins synthesis agonist (LIPCOR+) | 54 (44) | 50 |
| 12 (15) | Calcium channel antagonist (CHA-CA-) | 53 (47) | 28 |
| 13 (7) | Tumour necrosis factor α antagonist (TNF-A-) | 52 (62) | 15 |
| 14 (-) | Microtubule inhibitor (MICTUBE-) | 51 (-) | 6 |
| 15 (13) | 5-HT reuptake inhibitor (5HTU-) | 50 (53) | 38 |
| 16 (9) | Opioid µ receptor agonist (OPI-M-) | 50 (55) | 26 |
| 17 (10) | Estrogen agonist (ESTR+) | 50 (55) | 54 |
| 18 (-) | Cyclooxygenase 1 inhibitor (OX-C-1) | 50 (-) | 36 |
| 19 (16) | Insulin agonist (INS+) | 48 (45) | 17 |
| 20 (18) | Gene expression inhibitor (GE-EXP-) | 47 (44) | 0 |
| Table 4: Top 20 pharmacological activities. | |||